Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Other Non-Current Liabilities (2016 - 2025)

Perspective Therapeutics' Other Non-Current Liabilities history spans 15 years, with the latest figure at $342000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 936.36% year-over-year to $342000.0; the TTM value through Sep 2025 reached $342000.0, up 936.36%, while the annual FY2024 figure was $55000.0, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $342000.0 at Perspective Therapeutics, up from $284000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $668000.0 in Q3 2023 and bottomed at $19000.0 in Q2 2024.
  • The 5-year median for Other Non-Current Liabilities is $616000.0 (2021), against an average of $464529.4.
  • The largest annual shift saw Other Non-Current Liabilities plummeted 97.12% in 2024 before it soared 1394.74% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $624000.0 in 2021, then increased by 5.29% to $657000.0 in 2022, then grew by 1.67% to $668000.0 in 2023, then crashed by 91.77% to $55000.0 in 2024, then surged by 521.82% to $342000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Other Non-Current Liabilities are $342000.0 (Q3 2025), $284000.0 (Q2 2025), and $145000.0 (Q1 2025).